{"title":"Annual screening mammography lowers the risk of late-stage cancer","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35631","DOIUrl":null,"url":null,"abstract":"<p>Annual screening mammography is superior to biennial screening in reducing the risk of late-stage breast cancer detection and overall mortality, according to an observational study published in the <i>Journal of Clinical Oncology</i>.<span><sup>1</sup></span></p><p>Based on data from a cancer registry of 8145 patients with either a new breast cancer diagnosis or a prediagnosis screening history between 2004 and 2019, the study found that the percentage of late-stage cancers (defined as TNM stage IIIB or worse) significantly increased as the screening interval lengthened between mammography screenings. Late-stage cancers were found in 9% of patients undergoing annual mammography (interval ≤15 months), in 14% of those undergoing biennial mammography (≤27 months), and in 19% of those undergoing intermittent mammography (>27 months).</p><p>The findings were consistent regardless of age, menopausal status, or race. Mortality also was lower with annual mammography, with substantially worse overall survival seen with biennial and intermittent screening (relative hazards of 1.24 and 2.69, respectively).</p><p>The lead author of the study, Margarita L. Zuley, MD, chief of the Division of Breast Imaging in the Department of Radiology at the University of Pittsburgh, says that the study was performed to assess the effect of the screening mammography interval on actual patient outcomes because the current assessment is primarily based on modeling studies in the United States. “The study was performed to evaluate if the modeling estimates reflect actual patient outcomes,” she says. “We simply report the results of normal clinical practice, which has evolved over the time period.”</p><p>Liane Philpotts, MD, professor of radiology and biomedical imaging at Yale School of Medicine, says that the take-home message of the study is clear. “Annual screening results in a significantly lower risk of advanced or late-stage cancers and the results held for differing age groups, race, and menopausal status,” she says, adding that the findings “support a ‘one size fits all’ recommendation for annual screening for all women aged 40 and up.”</p><p>Dr Philpotts notes, however, that the study did not include breast density as a variable, which is linked to both higher breast cancer rates and reduced sensitivity of mammography in detecting breast cancer. This variable is found to be higher in specific ethnicities, particularly Asian women. The study included primarily White women, with only a small number of Asian women included. “Thus, the results of the study may not hold true for all ethnicities when density is also taken into account,” she says.</p><p>She also says that further studies will be needed to ascertain whether the advantages of three-dimensional mammography (or digital breast tomosynthesis) in detecting cancers at an earlier stage will translate into the feasibility of longer screening intervals.</p><p>The study did not look at outcomes according to the type of mammogram but included women who underwent film screen mammography, digital mammography with and without tomosynthesis, and tomosynthesis with synthetically derived mammography.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"130 24","pages":"4166"},"PeriodicalIF":6.1000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35631","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35631","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Annual screening mammography is superior to biennial screening in reducing the risk of late-stage breast cancer detection and overall mortality, according to an observational study published in the Journal of Clinical Oncology.1
Based on data from a cancer registry of 8145 patients with either a new breast cancer diagnosis or a prediagnosis screening history between 2004 and 2019, the study found that the percentage of late-stage cancers (defined as TNM stage IIIB or worse) significantly increased as the screening interval lengthened between mammography screenings. Late-stage cancers were found in 9% of patients undergoing annual mammography (interval ≤15 months), in 14% of those undergoing biennial mammography (≤27 months), and in 19% of those undergoing intermittent mammography (>27 months).
The findings were consistent regardless of age, menopausal status, or race. Mortality also was lower with annual mammography, with substantially worse overall survival seen with biennial and intermittent screening (relative hazards of 1.24 and 2.69, respectively).
The lead author of the study, Margarita L. Zuley, MD, chief of the Division of Breast Imaging in the Department of Radiology at the University of Pittsburgh, says that the study was performed to assess the effect of the screening mammography interval on actual patient outcomes because the current assessment is primarily based on modeling studies in the United States. “The study was performed to evaluate if the modeling estimates reflect actual patient outcomes,” she says. “We simply report the results of normal clinical practice, which has evolved over the time period.”
Liane Philpotts, MD, professor of radiology and biomedical imaging at Yale School of Medicine, says that the take-home message of the study is clear. “Annual screening results in a significantly lower risk of advanced or late-stage cancers and the results held for differing age groups, race, and menopausal status,” she says, adding that the findings “support a ‘one size fits all’ recommendation for annual screening for all women aged 40 and up.”
Dr Philpotts notes, however, that the study did not include breast density as a variable, which is linked to both higher breast cancer rates and reduced sensitivity of mammography in detecting breast cancer. This variable is found to be higher in specific ethnicities, particularly Asian women. The study included primarily White women, with only a small number of Asian women included. “Thus, the results of the study may not hold true for all ethnicities when density is also taken into account,” she says.
She also says that further studies will be needed to ascertain whether the advantages of three-dimensional mammography (or digital breast tomosynthesis) in detecting cancers at an earlier stage will translate into the feasibility of longer screening intervals.
The study did not look at outcomes according to the type of mammogram but included women who underwent film screen mammography, digital mammography with and without tomosynthesis, and tomosynthesis with synthetically derived mammography.
临床肿瘤学杂志》(Journal of Clinical Oncology)上发表的一项观察性研究显示,在降低乳腺癌晚期发现风险和总死亡率方面,乳腺放射摄影年度筛查优于两年一次的筛查。1该研究基于癌症登记处的数据,登记了2004年至2019年间8145名新诊断出乳腺癌或有诊断前筛查史的患者,研究发现,随着乳腺放射摄影筛查间隔时间的延长,晚期癌症(定义为TNM IIIB期或更差)的比例显著增加。在每年接受一次乳腺 X 射线照相检查(间隔时间≤15 个月)的患者中,9% 发现了晚期癌症;在每两年接受一次乳腺 X 射线照相检查(间隔时间≤27 个月)的患者中,14% 发现了晚期癌症;在每隔一段时间接受乳腺 X 射线照相检查(间隔时间为 27 个月)的患者中,19% 发现了晚期癌症。该研究的主要作者、匹兹堡大学放射学系乳腺成像科主任玛格丽塔-L-祖雷(Margarita L. Zuley)医学博士说,该研究旨在评估乳腺X光筛查间隔对患者实际结果的影响,因为目前的评估主要基于美国的模型研究。"她说:"进行这项研究是为了评估建模估算是否反映了患者的实际结果。"耶鲁大学医学院放射学和生物医学成像学教授、医学博士 Liane Philpotts 说,这项研究的启示很明确。"她补充说,研究结果 "支持对所有40岁及以上女性进行年度筛查的'一刀切'建议。"不过,Philpotts博士指出,这项研究没有将乳房密度作为一个变量,而乳房密度与乳腺癌发病率较高和乳腺X光检查发现乳腺癌的敏感性降低有关。这一变量在特定的种族,尤其是亚裔妇女中更高。这项研究主要包括白人妇女,只有少数亚裔妇女。"她还说,还需要进一步的研究来确定三维乳腺 X 光摄影(或数字乳腺断层合成术)在早期发现癌症方面的优势是否会转化为延长筛查间隔的可行性。该研究没有根据乳腺X光检查的类型来观察结果,但包括了接受胶片筛查乳腺X光检查、有断层合成和无断层合成的数字乳腺X光检查以及断层合成与合成乳腺X光检查的妇女。
期刊介绍:
The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society.
CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research